Skip to main content
. 2019 Jun;67(6):772–783. doi: 10.4103/ijo.IJO_449_19

Table 4.

Coats disease by decade in 351 eyes of 351 patients. Treatment features

Treatment features 1973-1979 n=18 eyes in 18 patients (%) 1980-1989 n=43 eyes in 43 patients (%) 1990-1999 n=66 eyes in 66 patients (%) 2000-2009 n=112 eyes in 112 patients (%) 2010-2018 n=112 eyes in 112 patients (%) P Total n=351 eyes in 351 patients (%)
Observation 7 (39) 9 (21) 22 (33) 23 (21) 12 (11) 0.002 73 (21)
Medical or laser therapy 9 (50) 27 (63) 42 (64) 84 (75) 99 (88) <0.001 261 (74)
Number of total treatments 2.9 (2, 1-6) 2.0 (1, 0-13) 1.8 (2, 1-4) 3.6 (3, 1-15) 4.5 (3, 1-26) 0.001 3.6 (3, 1-26)
Mean (median, range)
 Argon laser photocoagulation 5 (55) 9 (33) 16 (38) 45 (40) 71 (72) <0.001 146 (42)
  Number of treatments 2.0 (2, 1-4) 3.0 (2, 1-11) 1.2 (1, 1-2) 1.9 (2, 1-4) 2.3 (1, 1-20) 0.22 2.1 (1, 1-20)
  Mean (median, range)
 Cryotherapy 7 (78) 25 (93) 30 (71) 65 (58) 67 (68) 0.20 194 (55)
  Number of treatments 2.3 (2, 1-5) 2.0 (2, 1-6) 1.6 (1, 1-3) 2.3 (2, 1-9) 2.1 (2, 1-6) 0.22 2.1 (2, 1-9)
  Mean (median, range)
 Sub-Tenon corticosteroid injection 0 (0) 1 (4) 2 (5) 9 (8) 29 (29) <0.001 41 (12)
  Number of treatments NA 1.0 (1, 1-1) 1.0 (1, 1-1) 1.7 (1, 1-4) 1.2 (1, 1-3) 0.24 1.3 (1, 1-4)
  Mean (median, mode)
 Intravitreal corticosteroid injection 0 (0) 0 (0) 1 (2) 4 (4) 9 (9) 0.08 14 (4)
  Number of treatments NA NA 1.0 (1, 1-1) 1.8 (2, 1-3) 3.7 (1, 1-14) 0.67 2.9 (1, 1-26)
  Mean (median, range)
 Anti-VEGF 0 (0) 1 (4) 1 (2) 15 (13) 18 (18) 0.003 35 (10)
  Number of treatments NA 0.1 (0, 0-3) 1.0 (1, 1-1) 2.7 (1, 1-12) 4.2 (2, 1-20) 0.72 3.4 (2, 1-20)
  Mean (median, range)
Primary enucleation 2 (11) 7 (16) 2 (3) 5 (4) 1 (1) 0.001 17 (5)
No follow-up 6 (33) 10 (23) 23 (35) 36 (32) 28 (25) 0.51 103 (29)

Bold values indicate significant P. *Other signifies less common treatments such as scleral buckle, photodynamic therapy, transpupillary thermotherapy, and plaque radiotherapy, NA=Not applicable, VEGF=Vascular endothelial growth factor, Number of total treatments: Post-hoc analysis (Bonferroni test) showed a significant difference between groups 3 and 5 (P<0.001). There was no significant difference between any other groups (P>0.05)